Jean-Charles Soria/LinkedIn
May 6, 2025, 18:15
Jean-Charles Soria discusses MSI-H and ICI response in cancer treatment
Jean-Charles Soria, SVP and Oncology Therapeutic Area Head of Amgen, shared a post on LinkedIn:
“MSI-H = hallmark of mismatch repair (MMR) deficiency.
Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric.
But not all MSI-H/dMMR tumors are alike:
1.MSH2/MSH6 loss → ↑ TMB, better ICI response
2.PTEN/AKT1 mutations → ICI resistance
Checkpoint blockade is now 1L in CRC and endometrial.”
Title: Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Journal: Nature Reviews Clinical Oncology
Authors: Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb, Filippo Pietrantonio
More posts featuring Jean-Charles Soria on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 7, 2025, 09:49
May 7, 2025, 09:13